Google CEO Sundar Pichai makes his debut testimony before Congress.

John Fourier

2018-12-15 14:38:00 Sat ET

Google CEO Sundar Pichai makes his debut testimony before Congress. The post-mid-term-election House Judiciary Committee bombards Pichai with key questions on whether the Internet search company harbors political bias. Lawmakers further ask him about some recent Google plans to re-enter the Chinese market with its Project Dragonfly and user privacy initiatives. Pichai pushes back against several allegations and accusation of partisan bias. He emphasizes the fact that Google provides Internet platforms for both diverse and open perspectives and opinions while there is no shortage of them among Google executives and other employees.

Pichai leads the Internet search platform enterprise without political bias and thus works hard to ensure that all Google software products continue to operate that way. He also emphasizes the core conviction that any form of political bias would be inconsistent with the main principles and business interests of Alphabet, Google, and their affiliates.

The congressional testimony sheds new light on the Google PageRank black-box algorithm, which takes into account online content curation, backlink creation, and numerous other traffic-driven metrics for efficiently ranking webpages worldwide. However, this testimony leaves open the more urgent questions about the recent Google security breaches, bulk data collection practices, anti-competitive gambits, and potential antitrust regulations.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

France and Germany are the biggest beneficiaries of Sino-U.S. trade escalation.

Chanel Holden

2019-07-11 10:48:00 Thursday ET

France and Germany are the biggest beneficiaries of Sino-U.S. trade escalation.

France and Germany are the biggest beneficiaries of Sino-U.S. trade escalation, whereas, Japan, South Korea, and Taiwan suffer from the current trade stando

+See More

AYA Analytica financial health memo (FHM) blog post and podcast content curation with wise words of wisdom

Daisy Harvey

2019-04-30 07:15:00 Tuesday ET

AYA Analytica financial health memo (FHM) blog post and podcast content curation with wise words of wisdom

Through our AYA fintech network platform, we share numerous insightful posts on personal finance, stock investment, and wealth management. Our AYA finte

+See More

The Sino-U.S. trade war may be the Thucydides trap or a clash of Caucasian and non-Caucasian civilizations.

Chanel Holden

2019-06-03 11:31:00 Monday ET

The Sino-U.S. trade war may be the Thucydides trap or a clash of Caucasian and non-Caucasian civilizations.

The Sino-U.S. trade war may be the Thucydides trap or a clash of Caucasian and non-Caucasian civilizations. The proverbial Thucydides trap refers to the his

+See More

Michael Kors pays $2.3 billion to acquire the Italian elite fashion brand Versace.

Joseph Corr

2018-09-27 11:41:00 Thursday ET

Michael Kors pays $2.3 billion to acquire the Italian elite fashion brand Versace.

Michael Kors pays $2.3 billion to acquire the Italian elite fashion brand Versace. In accordance with Michael Kors's 5-year plan, the joint company grow

+See More

Carl Icahn mulls over steps to shake up the board of SandRidge Energy after it adopts a counter poison pill.

Jacob Miramar

2017-11-29 07:42:00 Wednesday ET

Carl Icahn mulls over steps to shake up the board of SandRidge Energy after it adopts a counter poison pill.

The octogenarian billionaire and activist investor Carl Icahn mulls over steps to shake up the board of SandRidge Energy after the oil-and-gas company adopt

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More